Penumbra's STORM-PE Trial Shows Superior Outcomes for CAVT in Pulmonary Embolism Treatment
Event summary
- STORM-PE trial results show CAVT plus anticoagulation led to significantly better functional outcomes at 90 days compared to anticoagulation alone for intermediate-high risk PE patients.
- Patients treated with CAVT walked 479m in the six-minute walk test vs. 368m for those on anticoagulation alone (P=0.003).
- 97% of CAVT-treated patients achieved NYHA Class I (no physical limitations) compared to 76% in the anticoagulation-only arm.
- STORM-PE enrolled 100 patients across 22 international sites, with results presented at SIR's Annual Scientific Meeting on April 13, 2026.
The big picture
Penumbra's STORM-PE trial results position CAVT as a potential game-changer in pulmonary embolism treatment, challenging the historical reliance on anticoagulation alone. With PE representing the third leading cause of cardiovascular death, this data could reshape treatment protocols and expand Penumbra's market leadership in thrombectomy solutions. The findings come at a time when endovascular therapies are gaining traction across multiple vascular conditions.
What we're watching
- Clinical Adoption
- Whether the STORM-PE results will accelerate integration of CAVT into future clinical guidelines for PE treatment.
- Market Expansion
- The pace at which Penumbra can expand Lightning Flash™ adoption beyond intermediate-high risk PE cases.
- Competitive Dynamics
- How established anticoagulation therapies and emerging endovascular solutions may respond to these findings.